Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies
Twist Bioscience (NASDAQ: TWST) has expanded its high-throughput antibody portfolio with the launch of the CHO Express Antibodies, complementing their existing HEK293 antibodies. This expansion aims to support biopharma companies by providing customizable, cost-effective, and scalable antibody production solutions. CHO cell lines are pivotal in biotherapeutic drug manufacturing, and Twist's new service can deliver sequence-perfect IgG antibodies in as few as 13 business days. The antibodies range from 15 μg to 3,000 μg and include detailed yield data for screening. This development improves the efficiency and reduces the costs associated with antibody discovery and production.
- Twist Bioscience launched CHO Express Antibodies, expanding its high-throughput antibody portfolio.
- CHO Express Antibodies can be delivered in as few as 13 business days, enhancing turnaround times.
- The new service provides customizable and scalable antibody production, supporting biopharma companies.
- Twist's antibodies range from 15 μg to 3,000 μg, offering flexibility for various research needs.
- Detailed yield data for each antibody sequence aids in effective candidate screening.
- None.
Insights
Twist Bioscience's expansion in its high-throughput IgG antibody portfolio with the introduction of CHO Express Antibodies is a significant development for the biotech sector. The use of CHO (Chinese Hamster Ovary) cells is a standard practice in biopharmaceutical manufacturing, especially for protein therapeutics. This addition will likely enhance Twist's market position, providing biopharma companies with more efficient and scalable options for antibody production.
CHO cells are preferred because they are well-characterized, offer high growth rates and can produce complex proteins similar to human cells. By offering antibodies produced in CHO cells, Twist is addressing a critical need in the early stages of biotherapeutic development. This could expedite the drug discovery process, making it more cost-effective and efficient for developers.
For a retail investor, this expansion underscores Twist's commitment to innovation and addressing industry challenges. It can also potentially drive higher revenue streams by attracting more biopharma customers looking for streamlined antibody production solutions.
From a financial perspective, Twist Bioscience's new offering can positively impact its revenue growth and market share. The high-throughput antibody production in CHO cells not only meets a pressing industry need but also positions Twist as a more integral partner in the biopharma supply chain. This could lead to increased order volumes, higher customer retention and expanded market penetration.
Additionally, the reduced turnaround times of 10 to 13 business days for producing antibodies suggest a more efficient use of resources and faster revenue cycles. However, investors should monitor how well Twist can manage the increased operational demands and whether this expansion translates into improved financial metrics in upcoming quarterly reports.
Short-term, there might be an increase in operating costs due to the scale-up process, but long-term, this strategic move should enhance profitability and drive shareholder value.
- Express Genes enable faster turnaround times
- Twist Express Antibodies, CHO starting at 13 business days
- Twist Express Antibodies, HEK293 starting at 10 business days
“With the majority of biotherapeutic drugs manufactured in CHO cell lines, expressing small-scale therapeutic antibody candidates in CHO for screening has become a vital first step to ensure successful downstream scale-up. We now provide a comprehensive portfolio of antibody production to further serve the biopharma market by offering both HEK293 with reduced turnaround times enabled by our Express Genes as well as the newly launched CHO cell line for Twist Express Antibodies,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By taking on the process of antibody development from sequence to protein, we meet the needs of therapeutic developers who currently make their own antibodies, a costly bottleneck in the discovery pipeline, providing them with a cost-effective, customizable, and scalable offering to support their research.”
Using its high-throughput antibody production workflow, Twist can generate large quantities of small-scale distinct antibodies for candidate and drug discovery screening. Antibodies are created from user-defined sequences using the customer’s expression system of choice, either CHO or HEK293. Twist Express Antibodies are sequence-perfect and high quality, delivered in as few as 10 business days.
Twist Express Antibodies, CHO
Twist Express Antibodies, CHO, are developed using a high-throughput antibody production workflow that yields IgG antibodies in quantities ranging from 15 μg up to 3,000 μg. The antibodies are made using sequence-verified perfect clonal genes for high quality. Twist also provides yield data on each antibody sequence to be used as a screening tool for candidate selection as well as control yield data to provide peace of mind and confidence of successful transfection and protein production. Turnaround time for Twist Express Antibodies, CHO, starts at 13 business days.
Twist Express Antibodies
Twist Express Antibodies provide a comprehensive and efficient solution to antibody production and purification. The process begins with a customer entering antibody sequences into Twist’s eCommerce ordering platform, where bioinformatic screening and gene scoring is used to filter out potentially non-viable sequences. From there, synthetic DNA is generated, which is either cloned into one of Twist’s IgG scaffold vectors, or a vector of the customer’s choice. Twist’s silicon-based DNA synthesis platform enables the simultaneous production of up to thousands of antibody genes, which enables flexible production of tens to thousands of distinct antibodies. Twist sequences the antibody genes to ensure that the precise order has been cloned correctly, every time. These antibodies are then produced in CHO or HEK293 cells, resin purified, and have a turnaround time starting at 10 business days for HEK293 and 13 business days for CHO.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding the ability of Twist Express Antibodies to provide a comprehensive and efficient solution to antibody production and purification, as well as our ability to meet the needs of therapeutic developers who currently make their own antibodies by providing them with a cost-effective, customizable, and scalable offering to support their research. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710374255/en/
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Source: Twist Bioscience Corporation
FAQ
What new product did Twist Bioscience launch?
How long does it take for Twist Bioscience to deliver CHO Express Antibodies?
What are the benefits of Twist Bioscience's new CHO Express Antibodies?
How does Twist Bioscience's CHO Express Antibodies support biopharma companies?
What is the range of antibody quantities provided by Twist Bioscience's new CHO Express Antibodies?
